This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blythe, D. Articles by Hackett, L P. Search for Related Content PubMed PubMed Citation Articles by Blythe, D. Articles by Hackett, L P. Social Bookmarking                   What's this?

Cardiovascular and neurological toxicity of venlafaxine

Intensive Care Unit, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, Perth, Western Australia 6009

L Peter Hackett

Clinical Pharmacology and Toxicology Laboratory, Western Australian Centre for Pathology and Medical Research, Hospital Avenue, Nedlands, Perth, Western Australia 6009

1. 1 We report a case of venlafaxine overdose and describe pharmacokinetic data on drug disposition.
   
2. 2 Case report. Serial venlafaxine levels were measured and drug half-life calculated and compared to data at therapeutic concentrations. Metabolite concentrations were also measured and the potential for toxicity described with reference to individual variation in such metabolism
   
3. 3 Venlafaxine can cause significant cardiac and neurotoxicity. Its potential for causing such toxicity may be dependent on whether an individual has the extensive metaboliser cytochrome CYP2D6 phenotype or the poor metaboliser phenotype
   

Key Words: venlafaxine • cardiotoxicity • neurotoxicity • pharmacokinetics

Human & Experimental Toxicology, Vol. 18, No. 5, 309-313 (1999)
DOI: 10.1191/096032799678840165


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Alexandrino-Silva, F. H. Nadalini Maua, A. G. de Andrade, and T. C. de Toledo Ferraz Alves Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms J Psychopharmacol, March 1, 2008; 22(2): 214 - 216. [Abstract] [PDF]

				S L Greene, P I Dargan, and A L Jones Acute poisoning: understanding 90% of cases in a nutshell Postgrad. Med. J., April 1, 2005; 81(954): 204 - 216. [Abstract] [Full Text] [PDF]

				S. CHEETA, F. SCHIFANO, A. OYEFESO, L. WEBB, and A. H. GHODSE Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000 The British Journal of Psychiatry, January 1, 2004; 184(1): 41 - 47. [Abstract] [Full Text] [PDF]

				I.M. Whyte, A.H. Dawson, and N.A. Buckley Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants QJM, May 1, 2003; 96(5): 369 - 374. [Abstract] [Full Text] [PDF]

				G C Hard Short-term adverse effects in humans of ingested mineral oils, their additives and possible contaminants-A review Human and Experimental Toxicology, March 1, 2000; 19(3): 158 - 172. [Abstract] [PDF]